Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2018 August;109(4) > Minerva Medica 2018 August;109(4):280-4

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Medica 2018 August;109(4):280-4

DOI: 10.23736/S0026-4806.18.05572-6

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

Benign prostatic hypertrophy: Pycnogenol® supplementation improves prostate symptoms and residual bladder volume

Andrea LEDDA 1, 2, Gianni BELCARO 1, 2 , Beatrice FERAGALLI 1, 2, Umberto CORNELLI 1, 2, Mark DUGALL 1, 2, Marcello CORSI 1, 2, Maria R. CESARONE 1, 2

1 IRVINE3 Labs, Chieti-Pescara University, Chieti, Italy; 2 International Agency for Pharma Standard Supplements (IAPPS), Chieti, Italy


PDF


BACKGROUND: The aim of this study was to evaluate the efficacy of Pycnogenol® supplementation in terms of safety and tolerability in the setting of preclinical or borderline, initial symptoms of benign prostatic hyperthrophy (BPH), in otherwise healthy subjects, using Pycnogenol® over a period of 60 days.
METHODS: Seventy-five healthy men with symptoms and signs of initial BPH were included. The subjects were divided into three groups: 1) control group using only the standard management (SM); 2) a group using SM plus Pycnogenol® 150 mg/day; 3) a group using standard pharmacological management.
RESULTS: BPH symptoms like emptying, frequency, intermittency, urgency, weak flow, straining, nocturia, were all significantly improved with Pycnogenol® (P<0.05) and the difference with both control groups was statistically significant (P<0.05).
CONCLUSIONS: Pycnogenol® may be an important option for self-management of BPH in otherwise healthy men.


KEY WORDS: Prostatic hyperthrophy - Dietary supplements - Prostate - Pycnogenol® - Nocturia

top of page